Global biopharma funding in June 2026 up 84% YoY and 30% MoM Globally (see Kevin Caliendo's note), biopharma funding in June 2026 showed a positive trend. Total funding reached approximately US$7.6bn, up 84% YoY and 30% MoM from May's US$5.9bn. The sequential improvement was primarily driven by a strong recovery in public financing, with IPO/follow-on funding increasing 52% YoY and 63% MoM, although there were 21 follow-on transactions and no featured IPOs. Meanwhile, VC/PE funding remained robust at about ...